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1607-551X/Copyright ª 2015, KaohsiuAbstract Transrectal-ultrasound-guided prostate biopsy (TRUS-PBx) is the standard proce-
dure for diagnosing prostate cancer. The procedure does cause some pain and discomfort;
therefore, an adequate analgesia is necessary to ensure patient comfort, which can also facil-
itate good-quality results. This prospective, randomized, double-blinded, placebo-controlled
study aimed to determine if intravenous (IV) paracetamol can reduce the severity of pain asso-
ciated with TRUS-PBx. The study included 104 patients, scheduled to undergo TRUS-PBx with a
suspicion of prostate cancer, that were prospectively randomized to receive either IV paracet-
amol (paracetamol group) or placebo (placebo group) 30 minutes prior to TRUS-PBx. All pa-
tients had 12 standardized biopsy samples taken. Pain was measured using a 10-point visual
analog pain scale during probe insertion, during the biopsy procedure, and 1 hour postbiopsy.
All biopsies were performed by the same urologist, whereas a different urologist administered
the visual analog pain scale. There were not any significant differences in age, prostate-
specific antigen level, or prostate volume between the two groups. The pain scores were signif-
icantly lower during probe insertion, biopsy procedure, and 1 hour postbiopsy in theeclare no conflicts of interest.
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IV paracetamol for TRUS-guided prostate biopsy 573paracetamol group than in the placebo group. In conclusion, the IV administration of paracet-
amol significantly reduced the severity of pain associated with TRUS-PBx.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Transrectal-ultrasound (TRUS)-guided prostate biopsy (PBx;
TRUS-PBx) is the standard procedure for diagnosing pros-
tate cancer (PCa). The procedure is recommended for pa-
tients with abnormal digital-rectal-examination (DRE)
findings or an elevated prostate-specific antigen (PSA) level
[1]. TRUS-PBx is known to cause pain and/or discomfort
with various different and conflicting ratios ranging from 7%
to 96% [2]. An interesting result has been observed from the
study of Irani et al [3] mentioning that 19% of the patients
that have undergone TRUS-PBx would refuse to undergo the
procedure again without any analgesia.
The severity of pain/discomfort is correlated with the
number of cores taken; thus, an adequate analgesia can
improve patient comfort during biopsy and increase the
diagnostic value of the procedure [4,5]; however, it was
also reported that the number of the cores and the severity
of pain are not correlated [6,7]. In addition, Kaver et al [8]
hypothesized the concept of pain accumulation, that is,
pain during TRUS-PBx gradually increases in severity from
the first core to the last.
Many factors are associated with pain during TRUS-PBx,
such as anal discomfort due to the TRUS probe and insertion
of needles into the prostate gland [9,10]. Periprostatic local
anesthetic infiltration is regarded as the best method for
managing pain during TRUS-PBx [11]; however, this method
is invasive, and a randomized trial reported that needle
punctures for lidocaine infiltration were more painful than
probe insertion and biopsy [12].
Intravenous (IV) paracetamol (acetaminophen) is
considered the first-line non-opioid analgesic for treating
mild to moderate pain. Although paracetamol’s central
analgesic effect is well known, its primary mechanism of
action, which may be inhibition of prostaglandin synthesis
or via an active metabolite influencing cannabinoid re-
ceptors, remains unknown [13].
The present prospective, randomized, double-blinded,
placebo-controlled study aimed to determine if IV para-
cetamol can reduce the severity of pain associated with
TRUS-PBx.
Methods
Between December 2009 and February 2011, 140 consecu-
tive patients underwent TRUS-PBx in our department, of
which 104 qualified for inclusion in the study. The study
flowchart is shown in Figure 1. The indications for PBx
included abnormal DRE findings and/or a PSA concentration
 4 ng/mL. The exclusion criteria were painful conditions
of the prostate, rectum, and anus (such as acute prostatitisor prostadynia, hemorrhoid, and anal fissure or stricture);
neurological conditions that can affect the perception of
pain; history of liver and/or kidney disease; and allergy to
paracetamol. In addition, patients who had undergone PBx
previously and/or were using any oral analgesic or narcotic
medication were excluded due to their potential to inter-
fere with the perception of pain. A written informed con-
sent was obtained from all patients. The study protocol was
approved by the Ethics Committee of Selcuk University
School of Medicine, and was performed in accordance with
the ethical standards laid down in the 1964 Declaration of
Helsinki and its later amendments.
Antibiotic prophylaxis was achieved via oral adminis-
tration of 500-mg ciprofloxacin, one tablet every 12 hours
starting 2 days prior to TRUS-PBx and 3 days postprocedure.
The patients were randomly assigned to receive 100-mL
(10 mg/mL) IV paracetamol (Perfalgan, Bristol-Myers
Squibb, Itxassou, France) for 15 minutes before TRUS-PBx
(paracetamol group), or 100-mL IV saline for 15 minutes
before TRUS-PBx (placebo group). The solutions in both
groups were infused from within a special black bag, so as
to blind the patients to which treatment they received.
TRUS-PBx was performed 30 minutes after the injection of
the solutions.
The patients were placed in the left lateral decubitus
position. The transrectal imaging was performed using a
LOGIQ 200 PRO Series ultrasonography device equipped
with a 6.5-MHz probe (GE Healthcare, Seoul, Korea). After
the insertion of the TRUS probe, the prostate gland was
imaged in longitudinal and sagittal planes for morphologic
evaluation and volume measurement. A standard of 12
cores were sampled from each patient by using an auto-
matic spring-loaded biopsy gun with an 18-gauge 22-cm
biopsy needle. All biopsies were performed by the same
urologist (O.K.) that was blinded to the preprocedure
analgesic treatment.
Following TRUS-PBx, each patient spent at least 1 hour
in the recovery room, during which time they were asked to
report the severity of their pain. Pain was evaluated by
using a 10-point visual analog scale (VAS) during probe
insertion and biopsy, and 1 hour after biopsy by a urologist
other than the one that performed the biopsies. All patients
had a follow-up visit at the outpatient clinic 1 week after
the TRUS-PBx to monitor for complications.
Data were analyzed with SPSS for Windows version 15.0
(SPSS Inc., Chicago, IL, USA) and NCSS 2007 (NCSS Inc.,
Kaysville, UT, USA). ShapiroeWilk analysis was used to
analyze the distribution of the age, PSA concentration, and
prostate volume. The descriptive analyses were given as
mean  standard deviation and range for the continuous
quantitative variables. The differences between the two
groups were analyzed with Student t test and
Figure 1. Flow diagram of the study. VAS Z visual analog scale.
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analyze the VAS scores within each group. The level of
statistical significance was set at p < 0.05.
Results
The paracetamol group included 53 patients, versus 51
patients in the placebo group. There were not any signifi-
cant differences in age, body-mass index, PSA value, and
prostate volume between the two groups (p > 0.05 for all).
The descriptive statistics are given in Table 1. The VAS painTable 1 Baseline demographic and clinical characteristics of th
Paracetamol group (n Z
Age (y) 67.9  8.2 (46e82)
BMI (kg/m2) 26.4  3.4 (21.6e32.3
PSA (ng/mL) 24.1  40.6 (2e152)
TRUS prostate volume (mL) 55.4  27.8 (17e155)
Complications
Hematuria 18 (33.9)
Rectal bleeding 12 (22.6)
Urinary infection 4 (7.5)
Fever 1 (1.8)
Urinary retention 2 (3.7)
Hematospermia 6 (11.3)
Data are presented as mean  standard deviation (range) or n (%).
BMI Z body-mass index; PSA Z prostate-specific antigen; TRUS Z trscores during probe insertion and TRUS-PBx, and 1 hour
after the procedure in both groups are shown in Table 2.
The VAS pain scores were highest in the paracetamol
group during TRUS-PBx and the lowest 1 hour post-TRUS-
PBx. There was no significant difference in the VAS pain
score during probe insertion or during TRUS-PBx (p > 0.05)
in the paracetamol group, whereas the VAS pain score 1
hour after TRUS-PBx was significantly lower than during
both probe insertion and TRUS-PBx (p < 0.001). In the
placebo group, the VAS pain score was also highest during
TRUS-PBx. In contrast to the paracetamol group, the VASe groups.
53) Placebo group (n Z 51) P
67.1  9.1 (49e91) >0.05
) 26.0  2.9 (22.2e34.1) >0.05
21.8  40.1 (5e158) >0.05
59.2  23.1 (17e132) >0.05
>0.05
20 (39.2)
14 (27.4)
4 (7.8)
2 (3.9)
1 (1.9)
5 (9.8)
ansrectal ultrasonography.
Table 2 Distribution of visual-analog-scale scores between the two groups.
Pain Paracetamol group (n Z 53) Placebo group (n Z 51) p
During probe insertion 0.82  0.48 (0e2) 1.54  0.86 (0e5) <0.001
During the procedure 0.91  0.32a (0e3) 2.59  0.79d (1e6) <0.001
1 h after the procedure 0.12  0.03b,c (0e1) 0.78  0.53e,f (0e2) <0.001
Data are presented as mean  standard deviation (range).
a Pain during probe insertion versus procedure: p > 0.05.
b Pain during probe insertion versus after procedure: p < 0.001.
c Pain during procedure versus after procedure: p < 0.001.
d Pain during probe insertion versus procedure: p < 0.01.
e Pain during probe insertion versus after procedure: p < 0.01.
f Pain during procedure versus after procedure: p < 0.001.
IV paracetamol for TRUS-guided prostate biopsy 575pain score during TRUS-PBx was significantly higher than
during probe insertion in the placebo group (p < 0.01). The
VAS pain score 1 hour post-TRUS-PBx in the placebo group
was significantly lower than during probe insertion
(p < 0.01) and during TRUS-PBx (p < 0.001).
Minor complications, including hematuria, rectal
bleeding, urinary infection, fever, urinary retention, and
hematospermia, were observed in both groups at similar
rates (Table 1). All complications were treated appropri-
ately on an outpatient basis without squeal.Discussion
PCa is the most common cancer among men when skin
cancer is excluded, and is the second leading cancer-
related cause of death [14]. Moreover, the number of the
newly and incidentally diagnosed PCa cases is increasing
due to the widespread use of PSA monitoring. For this
purpose, TRUS-PBx has become the gold standard proce-
dure, which is recommended for patients with abnormal
DRE findings or an elevated PSA concentration [1]. Anal
discomfort due to insertion and movements of the TRUS
probe, and insertion of needles into the prostate gland are
the most common causes of pain during TRUS-PBx [9,10]. It
was reported that the rectal wall above the dentate line,
which is pierced by the biopsy needle, has a decreased
sensorium, and most of the pain associated with TRUS-PBx
is caused by the penetration of the prostatic capsule, which
results in the stimulation of the sensory receptors located
in the capsule [9]. Therefore, an adequate analgesia is
necessary to ensure patient comfort, which can facilitate
good-quality results.
Paracetamol (acetaminophen), a widely prescribed drug
for the relief of pain, has a central analgesic effect medi-
ated via the activation of the descending serotonergic
pathways. Debate exists about its primary site of action,
which might be the inhibition of prostaglandin synthesis or
via an active metabolite affecting cannabinoid receptors. It
is assumed that paracetamol acts as a reducing cosubstrate
on the peroxidase site of prostaglandin H2 synthetase, and
decreases the availability of the ferryl protoporphyrin IX
radical cation involved in the conversion of arachidonic acid
to prostaglandin G2. Alternatively, it has also been postu-
lated that paracetamol’s mechanism of action might be
mediated by an active metabolite (p-aminophenol) that isconjugated with arachidonic acid to effect cannabinoid
receptors [13]. Paracetamol interferes less with platelet
function and does not prolong bleeding time, as compared
to nonsteroidal anti-inflammatory drugs (NSAIDs). It is
inexpensive and well tolerated, and has a safe therapeutic
dose. The analgesic efficacy of IV administration of 1-g
paracetamol was reported in patients following orthope-
dic surgery [15] and elective ambulatory surgery [16].
Periprostatic nerve block (PPNB), with bilateral in-
jections of a local anesthetic agent at the junction of the
base of the prostate and seminal vesicles, was first
described by Nash et al [17] in 1996. Although it is accepted
as the gold standard for pain relief, it does not prevent the
pain caused by the insertion of the TRUS probe into the
rectum, TRUS probe movements, or during transcapsular
infiltration of the local anesthetic agent. As such, various
doses of local anesthetic agent, injection locations, and
combinations of medications have been described for this
method, including injection only at the base of the pros-
tate, both at the base and the apex, and only at the apex
[8,17e19]. A prospective, randomized, controlled study by
Ozden et al [20] compared different doses (2.5 mL, 5 mL,
and 10 mL) of 1% lidocaine injection at the base only, or at
the base and apex of the prostate to saline injection. They
reported that PPNB with injection of 10-mL lidocaine
resulted in better pain relief than lower doses of lidocaine,
and that there was not a significant difference between
basal only versus basal plus apical injection. Despite all the
research performed to date, there remains a lack of
consensus on the optimal local anesthetic technique.
As PPNB may not always be sufficient to reduce pain,
several multimodal approaches that combined PPNB with
other pain medications have been studied, including
intrarectal anesthetic gel [21,22] or anes-
theticemyorelaxant cream [23]; diclofenac administered
intramuscularly [24], dermally [25], or intrarectally [26,27];
IV ketorolac [28]; oral rofecoxib [29]; paracetamol plus
codeine [30]; and tramadol versus intramuscular midazolam
[31]. In general, these studies conclude that additional
pain-relief methods lower pain and/or discomfort experi-
enced during insertion and movements of the TRUS probe,
as PPNB alone is not always effective [11,32].
It was reported by two randomized studies that admin-
istration of intrarectal lidocaineeprilocaine or lidocai-
neenifedipine cream in addition to standard PPNB lowered
pain during TRUS-PBx, especially during insertion and
576 O. Kilic et al.movements of the TRUS probe [21,23]. Both studies
concluded that the combination of PPNB and lidocainee-
prilocaine/nifedipine cream was more effective than PPNB
alone, and that the combination treatment should be the
standard regimen. These findings were subsequently sup-
ported by those of Anup et al [22], who reported that the
combination of PPNB and perianaleintrarectal lidocainee-
prilocaine cream was more effective than either of the two
regimens alone.
The administration of diclofenac via intramuscular in-
jection, dermal patch, or rectal suppository was evaluated
for pain relief during TRUS-PBx. Bhomi et al [24] reported
that there was a significant difference between the PPNB
group and the control group, and between the PPNB group
and the diclofenac group. Interestingly, they did not
observe a difference between the diclofenac and control
groups, and concluded that PPNB improves patient toler-
ance of TRUS-PBx better than diclofenac. By contrast,
Griwan et al [25] reported that a diclofenac patch signifi-
cantly reduced pain 1 hour, 2 hours, and 4 hours post-TRUS-
PBx, but not during the procedure. They concluded that
diclofenac could be used as an adjunct treatment, and that
PPNB together with a diclofenac patch might provide
adequate analgesia during and after TRUS-PBx. A random-
ized, controlled trial reported that the combination of
PPNB with levobupivacaine and diclofenac suppository was
superior to PPNB only and diclofenac suppository only [26].
Apart from these studies, Haswir and Umbas [27] eval-
uated the efficacy of oral morphine sulfate only or diclo-
fenac suppository only for pain relief during TRUS-PBx, and
reported no difference between the methods. In another
study with a similar setting, Olmez et al [33] observed that
pain associated with TRUS-PBx was higher in their saline
group, that both their tramadol and lornoxicam groups had
significantly lower pain scores than the saline group, and
that the tramadol group had the lowest score; as in the
study by Haswir and Umbas [27], PPNB was not used. The
tramadol group also had the lowest level of discomfort than
the other two groups, and the percentage of patients that
reported they would not undergo another TRUS-PBx in the
future was lower in the tramadol and lornoxicam groups
than in the saline group.
Moinzadeh et al [29] compared the oral administration of
50-mg rofecoxib (a selective inhibitor of cyclooxygenase-2)
only and placebo, and did not observe a decrease in pain
between the two methods. Based on their findings, they
suggested that systemic administration of NSAIDs may not
be suitable for pain relief during TRUS-PBx. In contrast, 60-
mg IV ketorolac before TRUS-PBx significantly reduced pain
[28]. The author concluded that a single dose of IV ketor-
olac was efficient for pain relief without any adverse ef-
fects, despite its NSAID properties.
The literature includes a few studies on the use of
paracetamol during TRUS-PBx, but none have examined the
IV route of administration [30,34,35]. Pendleton et al [34]
randomized patients scheduled to undergo TRUS-PBx into
two groups: Group 1 received the combination of tramadol
plus acetaminophen together with PPNB, and Group 2
received placebo with PPNB. They reported that the com-
bination of tramadol plus acetaminophen together was
associated with lower pain scores. Subsequently, Visapa¨a¨
and Taari [30] studied the effect of the combined oraladministration of 500-mg paracetamol and 30-mg codeine
together with PPNB, and reported that the VAS pain scores
were lower in the combination treatment group. A recent
prospective, randomized, single-blinded study compared
oral paracetamol and rectal EMLA cream to conventional
PPNB [35]. The pain scores in these two groups were
significantly lower than in the PPNB group, and the per-
centage of patients that reported they would undergo
TRUS-PBx again using the same pain relief method was
significantly higher in the paracetamol and rectal EMLA
groups. A summary of the prospective, randomized,
controlled studies is listed in Table 3.
Based on the similar thoughts from these studies
[30,34,35], earlier findings that paracetamol is a good
choice for pain relief [15,16], and our limited experience
using paracetamol during TRUS-PBx (only 2 patients in
whom PPNB could not be used due to allergy to local an-
esthetics), we performed the present study to determine
the efficiency of a single dose of 1-g IV paracetamol for pain
control during TRUS-PBx. In the present study, paracetamol
significantly decreased the severity of pain during probe
insertion and biopsy, as well as 1 hour postbiopsy. In
contrast to some of the previous studies, in the present
study the VAS pain scores were highest during TRUS-PBx,
not during probe insertion, which is consistent with some
other reports [9]. This might be due to the assumption that
movements of the TRUS probe while obtaining biopsy
samples from lateral parts of the prostate and piercing of
the prostatic capsule cause the most pain.
The present study has certainly some limitations. Firstly,
the patient population was small. Although we sought to
recruit at least 60 patients for each group, due to the use of
exclusion criteria, only 53 patients and 51 patients were
enrolled in the paracetamol and placebo groups, respec-
tively. Secondly, it might have been more useful to have
included a PPNB group for comparing the efficacy of IV
paracetamol not only to placebo, but also to a standard
regimen (PPNB). Thirdly, we did not evaluate the liver and
kidney functions of the patients with laboratory tests; we
only asked if the patients had a history of any disease that
may interfere with paracetamol usage. It should be kept in
mind that paracetamol should not be used in patients with
a liver and/or kidney disease, as in rare cases it can cause
hepatic or renal insufficiency.
In contrast to its limitations, this study has some
strength. Firstly, all biopsies were performed by the same
urologist that was blinded to the analgesic method used,
and the VAS pain scores were evaluated by a different
urologist. Secondly, a readily available, inexpensive, and
well-tolerated analgesic agentdparacetamoldwas evalu-
ated. Thirdly, although the duration of TRUS-PBx in the
paracetamol group was not compared to that of the con-
ventional method (PPNB), we think that the use of IV
paracetamol, as described herein, reduces the duration of
TRUS-PBx, as no time is required for periprostatic injection,
which might also decrease patient anxiety. Lastly, as there
is a risk of vasovagal syncope during TRUS-PBx, opening an
IV line for paracetamol administration can facilitate man-
agement of a hypotensive attack in a timely manner.
In conclusion, to the best of our knowledge, the present
study is the first to evaluate the efficacy of paracetamol for
control of pain associated with TRUS-PBx. Based on the
Table 3 List of prospective, controlled studies that have compared different analgesia methods during transrectal-
ultrasound-guided prostate biopsy.
Study Year Study
type
Treatments Results & notes
Giannarini et al [21] 2009 PRC PILP cream þ PPNB versus PILP cream
only versus PPNB only versus no
anesthesia
(1) The combination treatment provides
better pain control than the other 2
modalities alone, as well as the no-
anesthesia group.
(2) The magnitude of better pain control is
higher in men  65 y, with larger
prostate  49 cc, & with lower anorectal
compliance.
(3) The complication rates are similar.
Anup et al [22] 2013 PRC PILP cream þ PPNB versus PPNB only
versus PILP cream only
(1) The combination provides better anal-
gesia, especially in patients < 60 y,
prostate volume > 50 cc, & lower ano-
rectal compliance.
(2) There was no increase in complication
rates.
Cantiello et al [23] 2009 PRC PPNB versus PPNB þ intrarectal
anestheticemyorelaxant cream
(1) The combination group had lower pain
scores during probe insertion, during
periprostatic infiltration, 30 min after
the biopsy, & in the evening of the
biopsy.
(2) No difference was observed during the
procedure & on the day after biopsy.
Bhomi et al [24] 2007 PC PPNB versus 75-mg diclofenac
sodium intramuscularly versus
control
(1) The difference was significant between
PPNB & diclofenac, & between PPNB &
control.
(2) There was no difference between the
diclofenac & control groups.
Griwan et al [25] 2012 PRC PPNB versus diclofenac patch
versus control
(1) The diclofenac patch is better after
TRUS-PBx, but not during the
procedure.
(2) The authors advise that the combination
would be better.
Aktoz et al [26] 2010 PRC PPNB þ diclofenac suppository
versus PPNB only versus diclofenac
suppository only
(1) The combination therapy was better
than the other 2 groups.
(2) TRUS-PBx lowers the mean IIEF-5 scores
1 mo after biopsy, but medium-term
erectile function (IIEF-5 3 mo after
biopsy) is not affected.
Haswir & Umbas [27] 2008 PRC Oral morphine sulfate 10 mg only
versus diclofenac suppository
100 mg only
No difference was observed between the 2
groups.
Olmez et al [33] 2008 PRC Tramadol 100 mg intramuscularly
versus lornoxicam 8 mg intramuscularly
versus saline intramuscularly
(1) The tramadol group had the lowest pain
& discomfort.
(2) The lornoxicam group was better than
the control group.
(3) The percentage of patients who refused
to undergo another TRUS-PBx was lower
in tramadol & lornoxicam groups.
Moinzadeh et al [29] 2003 PRC Oral rofecoxib 50 mg versus placebo (1) No difference was observed in pain
scores.
(2) The authors concluded that systemic
administration of NSAIDs may not be
suitable.
Mireku-Boateng [28] 2004 PRC Ketorolac 60 mg intravenously versus
control
Ketorolac was efficient without side effects.
(continued on next page)
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Table 3 (continued )
Study Year Study
type
Treatments Results & notes
Visapa¨a¨ & Taari [30] 2009 PRC Oral paracetamol 500 mg þ oral codeine
30 mg þ PPNB versus PPNB only
The combination treatment was better with
lower pain scores.
Pendleton et al [34] 2006 PRC Oral tramadol 75 mg þ oral paracetamol
650 mg þ PPNB versus placebo þ PPNB
The addition of tramadol þ paracetamol
lowered the pain scores significantly.
Kim et al [35] 2011 PRC Oral paracetamol 650 mg versus rectal
EMLA cream versus PPNB
(1) Both paracetamol & EMLA cream groups
had similar VAS scores; those are both
lower than PPNB alone.
(2) The patients willing to undergo another
TRUS-PBx with the same analgesia
method were the higher paracetamol &
EMLA cream groups.
(3) All patients were given 50-mg tramadol
intravenously 30 min before the
procedure.
IIEFZ International Index of Erectile Function; NSAIDs Z nonsteroidal anti-inflammatory drugs; PC Z prospective, controlled;
PILP Z perianaleintrarectal lidocaine and prilocaine; PPNB Z periprostatic nerve block; PRC Z prospective, randomized, controlled;
TRUS-PBx Z transrectal-ultrasound-guided prostate biopsy; VAS Z visual analog scale.
578 O. Kilic et al.present findings, we think that a single IV dose of 1-g
paracetamol can be safely and effectively used to decrease
the severity of pain experienced during and after TRUS-
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